23rd Annual Update in Pulmonary Hypertension

This live CE accredited activity is the only New England symposium that illustrates novel pathways implicated in the pathogenesis of pulmonary vascular disorders and provides state of the art therapeutic approaches to the management of pulmonary hypertension. This education is accomplished via a combination of didactic lectures, case-based plenary and breakout discussions that feature leading experts as presenters and panelists. All presentations will be based on current evidence-based guidelines, research, and patient-centered outcomes.

Educational Outcome

This CE activity offers new and experienced healthcare providers state of the art education, recent data, case discussions, and practical guidance on the optimal screening and management of patients who have or are suspected of having pulmonary hypertension. It is expected that learners will utilize this education to make more informed treatment decisions that will measurably improve patient outcomes.

Objectives

After completing this activity, the participant should be better able to:

• Review clinical trial evidence on the safety and efficacy of emerging drug treatment options for PH, as well as novel pathways under development
• Evaluate new and existing therapeutic options for ILD-PH, as well as strategies for earlier recognition and interventions for this patient population
• Utilize an interactive, case-based learning approach in the discussion of managing PH patients with challenging comorbidities, such as renal disease, cancer, non-methamphetamine drug-induced PH, and others
• Develop an evidence-based management plan for pulmonary hypertension that incorporates use of imaging modalities, risk assessment tools, pharmacologic strategies, and routine follow-up to optimize outcomes
• Discuss the use of combination therapies, transition treatment strategies, and add-on treatments in the management of PAH
• Assess Guideline-Directed Medical Therapy for HFpEF and HFrEF and novel pathways in development
• Recognize the complexities or treatment decisions in patients with CTD-associated PAH and differences from CTD-associated ILD-PH
• Explore how to incorporate a collaborative model between patients, families, and healthcare providers to optimize shared decision-making and improve outcomes

Target Audience

This activity is intended for physicians (pulmonologists, cardiologists, rheumatologists and general practitioners), fellows, residents, nurse practitioners, registered nurses and other healthcare practitioners engaged in the care of patients with pulmonary arterial hypertension.